Shared on 13 Nov 25
Fair value Increased 5.03%BIOCON: Revenue Outlook And Global Expansion Likely To Support Steady Performance
Analysts have raised Biocon's fair value price target from ₹376.70 to ₹395.65, citing improved revenue growth projections and profit margins as key drivers for the upgrade. What's in the News Biocon announced the public funding of YESAFILI (aflibercept), a biosimilar to EYLEA, on the Ontario Drug Benefit Formulary in Canada for retinal disease treatment.
Shared on 05 Oct 25
Fair value Decreased 0.90%Analysts have lowered Biocon's price target slightly from ₹380.11 to ₹376.70, citing marginal adjustments in the discount rate and projected earnings metrics. Analyst Commentary Market watchers have weighed in on Biocon's valuation following the recent adjustment to its price target.
Shared on 23 Apr 25
Fair value Decreased 11%AnalystConsensusTarget has decreased revenue growth from 16.0% to 12.8%, increased profit margin from 6.9% to 7.8%, decreased future PE multiple from 41.9x to 35.6x and increased shares outstanding growth rate from -0.0% to -0.0%.
Shared on 17 Apr 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 09 Apr 25
Fair value Increased 2.93%AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 26 Mar 25
Fair value Decreased 4.98%AnalystConsensusTarget has decreased future PE multiple from 42.7x to 38.0x and increased shares outstanding growth rate from -0.0% to 0.0%.
Shared on 19 Mar 25
AnalystConsensusTarget made no meaningful changes to valuation assumptions.
Shared on 12 Mar 25
Fair value Increased 23%AnalystConsensusTarget has increased revenue growth from 14.3% to 16.1% and increased future PE multiple from 37.3x to 42.8x.